• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.

作者信息

McDuffee E, Aue G, Cook L, Ramos-Delgado C, Shalabi R, Worthy T, Vo P, Childs R W

机构信息

Department of Hematology, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

出版信息

Bone Marrow Transplant. 2017 May;52(5):759-761. doi: 10.1038/bmt.2016.346. Epub 2017 Jan 9.

DOI:10.1038/bmt.2016.346
PMID:28067871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9069644/
Abstract
摘要

相似文献

1
Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.肿瘤消退与类固醇难治性移植物抗宿主病同时出现，凸显了异基因造血干细胞移植后程序性死亡蛋白1阻断治疗的缺陷。
Bone Marrow Transplant. 2017 May;52(5):759-761. doi: 10.1038/bmt.2016.346. Epub 2017 Jan 9.
2
Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.异基因干细胞移植后伴有活动性移植物抗宿主病的复发难治性霍奇金淋巴瘤的低剂量程序性死亡受体1抑制治疗
Br J Haematol. 2019 Mar;184(5):840-844. doi: 10.1111/bjh.15186. Epub 2018 Mar 13.
3
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.异基因造血细胞移植后复发淋巴瘤的程序性死亡受体-1阻断治疗：缓解率高但移植物抗宿主病频繁。
Blood. 2017 Jul 13;130(2):221-228. doi: 10.1182/blood-2017-01-761346. Epub 2017 May 3.
4
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.复发/难治性淋巴瘤患者接受PD-1阻断治疗后进行异基因造血干细胞移植的安全性和有效性
Blood. 2017 Mar 9;129(10):1380-1388. doi: 10.1182/blood-2016-09-738385. Epub 2017 Jan 10.
5
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.异基因造血干细胞移植后纳武利尤单抗治疗复发霍奇金淋巴瘤的疗效和耐受性。
Blood. 2017 May 4;129(18):2471-2478. doi: 10.1182/blood-2016-11-749556. Epub 2017 Mar 7.
6
MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD.一名难治性儿童T细胞急性淋巴细胞白血病患者通过抗程序性细胞死亡1（PD-1）抗体治疗获得微小残留病缓解，但引发了致命的移植物抗宿主病。
Bone Marrow Transplant. 2017 Aug;52(8):1221-1224. doi: 10.1038/bmt.2017.107. Epub 2017 Jun 5.
7
Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.异基因干细胞移植后难治性霍奇金淋巴瘤采用低剂量纳武单抗治疗成功。
Int J Hematol. 2017 Jul;106(1):141-145. doi: 10.1007/s12185-017-2181-9. Epub 2017 Jan 17.
8
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.PD-1 阻断可诱导异基因造血干细胞移植后复发的经典霍奇金淋巴瘤缓解。
J Immunother Cancer. 2017 Feb 21;5:11. doi: 10.1186/s40425-017-0211-z. eCollection 2017.
9
Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.抗程序性细胞死亡-1单克隆抗体在异基因造血细胞移植前后用于复发或难治性霍奇金淋巴瘤的安全性和有效性：一项多中心回顾性研究
Int J Hematol. 2020 Nov;112(5):674-689. doi: 10.1007/s12185-020-02960-4. Epub 2020 Aug 3.
10
Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.一名霍奇金淋巴瘤患者中由程序性死亡受体1（PD-1）抑制剂帕博利珠单抗诱发的致命性移植物抗宿主病。
Bone Marrow Transplant. 2016 Sep;51(9):1268-70. doi: 10.1038/bmt.2016.111. Epub 2016 Apr 25.

引用本文的文献

1
PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome.急性髓系白血病和骨髓增生异常综合征异基因移植后复发的PD-1抑制作用。
Blood Adv. 2025 Aug 12;9(15):3878-3886. doi: 10.1182/bloodadvances.2024015200.
2
The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation.免疫检查点阻断对异基因造血干细胞移植结局的影响。
Front Immunol. 2024 Nov 20;15:1491330. doi: 10.3389/fimmu.2024.1491330. eCollection 2024.
3
Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.阻断跨 PD-L1 与 CD80 的相互作用增强抗肿瘤免疫。
Proc Natl Acad Sci U S A. 2023 Apr 18;120(16):e2205085120. doi: 10.1073/pnas.2205085120. Epub 2023 Apr 10.
4
Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors.造血干细胞移植后复发：检查点抑制剂的作用
Health Sci Rep. 2022 Mar 8;5(2):e536. doi: 10.1002/hsr2.536. eCollection 2022 Mar.
5
Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival.异基因造血干细胞移植后可溶性程序性死亡蛋白 1 水平低预示中重度慢性移植物抗宿主病和总体生存不良。
Front Immunol. 2021 Sep 24;12:694843. doi: 10.3389/fimmu.2021.694843. eCollection 2021.
6
Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.病例报告：异基因造血干细胞移植后接受 PD-1 阻断联合治疗导致致命移植物抗宿主病的急性髓系白血病。
Front Immunol. 2021 Apr 1;12:639217. doi: 10.3389/fimmu.2021.639217. eCollection 2021.
7
Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?程序性死亡蛋白1（PD-1）-程序性死亡配体（PD-L）阻断疗法在急性髓系白血病中有立足之地吗？
Pharmaceuticals (Basel). 2021 Mar 24;14(4):288. doi: 10.3390/ph14040288.
8
Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review.在接受异基因细胞移植的淋巴恶性肿瘤患者中使用检查点抑制剂：综述。
Bone Marrow Transplant. 2021 Aug;56(8):1784-1793. doi: 10.1038/s41409-021-01268-z. Epub 2021 Mar 19.
9
Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.髓系疾病中疾病复发的生物学：对干细胞移植后预防和治疗疾病复发策略的启示
J Clin Oncol. 2021 Feb 10;39(5):386-396. doi: 10.1200/JCO.20.01587. Epub 2021 Jan 12.
10
Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.白血病免疫逃逸的机制及其在单倍体造血细胞移植后复发中的作用。
Front Immunol. 2020 Feb 25;11:147. doi: 10.3389/fimmu.2020.00147. eCollection 2020.

本文引用的文献

1
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.纳武利尤单抗用于自体干细胞移植和维布妥昔单抗均治疗失败后的经典型霍奇金淋巴瘤：一项多中心、多队列、单臂2期试验。
Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.
2
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.伊匹单抗用于异基因移植后复发的患者。
N Engl J Med. 2016 Jul 14;375(2):143-53. doi: 10.1056/NEJMoa1601202.
3
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.在接受维布妥昔单抗治疗失败的经典型霍奇金淋巴瘤患者中使用帕博利珠单抗进行程序性死亡-1阻断治疗。
J Clin Oncol. 2016 Nov 1;34(31):3733-3739. doi: 10.1200/JCO.2016.67.3467.
4
Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.一名霍奇金淋巴瘤患者中由程序性死亡受体1（PD-1）抑制剂帕博利珠单抗诱发的致命性移植物抗宿主病。
Bone Marrow Transplant. 2016 Sep;51(9):1268-70. doi: 10.1038/bmt.2016.111. Epub 2016 Apr 25.
5
Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective.在异基因干细胞移植后复发的经典型霍奇金淋巴瘤患者中靶向PD-1通路是安全有效的。
Oncotarget. 2016 Mar 15;7(11):13260-13264. doi: 10.18632/oncotarget.7177.
6
Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.纳武单抗用于异基因干细胞移植后难治性霍奇金淋巴瘤患者。
Bone Marrow Transplant. 2016 Mar;51(3):443-5. doi: 10.1038/bmt.2015.266. Epub 2015 Nov 9.
7
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.纳武利尤单抗治疗复发或难治性霍奇金淋巴瘤的 PD-1 阻断作用。
N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.
8
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.宿主程序性死亡配体 1 的表达优于程序性死亡配体 2 的表达，调节移植物抗宿主病的致死率。
Blood. 2013 Oct 24;122(17):3062-73. doi: 10.1182/blood-2013-05-500801. Epub 2013 Sep 12.
9
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.组成型 AP-1 活性和 EBV 感染诱导霍奇金淋巴瘤和移植后淋巴组织增生性疾病中的 PD-L1：对靶向治疗的影响。
Clin Cancer Res. 2012 Mar 15;18(6):1611-8. doi: 10.1158/1078-0432.CCR-11-1942. Epub 2012 Jan 23.
10
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.整合分析揭示了结节性硬化性霍奇金淋巴瘤和原发性纵隔大 B 细胞淋巴瘤中 9p24.1 选择性扩增、PD-1 配体表达增加以及 JAK2 进一步诱导。
Blood. 2010 Oct 28;116(17):3268-77. doi: 10.1182/blood-2010-05-282780. Epub 2010 Jul 13.